

Reference	Reason for exclusion
Fisher 2000 <sup>143</sup>	Short report
Georgoulas 2003 <sup>144</sup>	Interim analysis on incomplete patient sample
Gridelli 2008 <sup>145</sup>	No outcome data – rationale and protocol only
Gridelli 2007 <sup>146</sup>	Rofecoxib (withdrawn)
Grigorescu 2002 <sup>147</sup>	Quasi-randomised
Leong 2003 <sup>148</sup>	Amifostine (Ethyol®, LABORATOIRES Genopharm) (cytoprotective adjuvant; indication for NSCLC withdrawn 2005)
Miller 2003 <sup>149</sup>	Dosing study using sequentially enrolled cohorts
O'Brien 2004 <sup>150</sup>	PLAT-based chemotherapy with or without SRL172 (killed <i>Mycobacterium vaccae</i> suspension)
Ramalingam 2006 <sup>151</sup>	Subanalysis by age
Vansteenkiste 2003 <sup>152</sup>	Detailed individual symptom control analysis, influence of CIS use, age, PS and duration of treatment
<sup>a</sup> Gao 2005 <sup>153</sup>	Unclear if patients had previous chemotherapy
<sup>a</sup> Lin 2002 <sup>154</sup>	Not a RCT
<sup>a</sup> Liu 2006 <sup>155</sup>	Unclear if patients had previous chemotherapy
Semrau 2003 <sup>156</sup>	No English abstract
<sup>a</sup> Teng 2003 <sup>157</sup>	Not a RCT
<sup>a</sup> Xu 2006 <sup>158</sup>	Does not report survival data
<sup>a</sup> Zhang 2008 <sup>159</sup>	Unclear if patients had previous chemotherapy

<sup>a</sup> Translated.